Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD ... However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the ...

In the case of a PROTAC, this binding involves an E3 ligase. Figure 1: An illustration from Arvinas showing the mechanism of proteolysis-targeting chimeras (PROTACs). Ultimately, the disease ...

Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...

A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to facilitate the formation of a ternary complex, leading to ubiquitination and ultimate ...

Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

CUL2 ZYG11B known as the substrate receptor of cullin-2 RING E3 ligase, is bound by SARS-CoV ... and offers valuable insights for optimizing PROTAC-based drug design based on NTH CUL2 ZYG11B ...

Multiple E3 ubiquitin ligases and deubiquitinating enzymes ... However, new strategies, including PROTAC, aim to enhance specificity and reduce toxicity in solid tumors. This study underscores ...

Yang et al. developed a proteolysis-targeting chimera (PROTAC) 753b, which targets BCL-xL and BCL-2 to the E3 ubiquitin ligase VHL, and showed that it removed senescent cells specifically from the ...